Evidence map›Paper›PMID 31880039›Full record

ArticleThe Kaohsiung journal of medical sciences2020

miR-574-3p inhibits proliferation and invasion in esophageal cancer by targeting FAM3C and MAPK1.

Ling-Li Jin, Shao-Jun Zhang, Guang-Xin Lu, Fei Lv, Rui Shang, Jie Yang

Open access · goldAbstract read
In one paragraph

Article in The Kaohsiung journal of medical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ling-Li JinDepartment of Gastroenterology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, P.R. China.
Shao-Jun ZhangDepartment of Health Management Center, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, P.R. China.ORCID https://orcid.org/0000-0002-7747-6643
Guang-Xin LuDepartment of Gastroenterology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, P.R. China.
Fei LvDepartment of Gastroenterology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, P.R. China.
Rui ShangDepartment of Gastroenterology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, P.R. China.
Jie YangDepartment of Health Management Center, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, P.R. China.
Hubei University of Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Esophageal cancer is considered as one of the leading malignancies. MicroRNA-574-3p (miR-574-3p) was used as a postoperative prognostic indicator in patients with esophageal squamous cell carcinoma. However, the underlying mechanism miR-574-3p involvement in esophageal cancer remains unclear. In this study, the expression of miR-574-3p was reduced in esophageal cancer tissues and cells. In vitro, miR-574-3p mimics and inhibitor were transfected into esophageal cancer cells (TE-1 and TE-8 cells) to up- or downregulating of miR-574-3p. miR-574-3p inhibited proliferation, migration and invasion, and promoted apoptosis in esophageal cancer cells. In addition, miR-574-3p was confirmed to target family with sequence similarity 3 member C (FAM3C) and mitogen-activated protein kinase 1 (MAPK1). miR-574-3p suppressed phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) and rapidly accelerated fibrosarcoma (Raf)/mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling via regulating FAM3C and MAPK1. In vivo, overexpression of miR-574-3p suppressed tumor growth in mice. Our findings indicated that miR-574-3p repressed proliferation and invasion of esophageal cancer via regulation of FAM3C and MAPK1, which provides a new biomarker for esophageal cancer treatment.

Indexed as

AnimalsBase SequenceCell Line, TumorCell MovementCell ProliferationCytokinesEsophageal NeoplasmsFemaleGene Expression Regulation, NeoplasticHumansMaleMAP Kinase Signaling SystemMice, Inbred BALB CMicroRNAsMiddle AgedMitogen-Activated Protein Kinase 1CytokinesFAM3C protein, humanMAPK1 protein, humanMicroRNAsMIRN574 microRNA, humanMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase KinasesNeoplasm ProteinsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktesophageal cancerFAM3CinvasionMAPK1 proliferationmiR-574-3p

Identifiers

PMID31880039
PMCPMC11896219
OpenAlexW2998666485

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.